HOLTER-ECG: Automated HRV analysis and QTc monitoring for rheumatic disease patients on HCQ and JAK inhibitors

HCQ and JAK inhibitors carry cardiac risks requiring monitoring. HOLTER-ECG implements Pan-Tompkins R-peak detection, time/frequency HRV (SDNN, RMSSD, pNN50, LF/HF per ESC Task Force DOI:10.1161/01.CIR.93.5.1043), and Bazett/Fridericia QTc. Drug-specific assessment for HCQ, HCQ+azithromycin, and JAK inhibitors. Demo: synthetic 5-min = 359 beats, SDNN 23.9ms, QTc 380ms SAFE. Limitation: synthetic ECG, simplified Pan-Tompkins. Authors: Zamora-Tehozol EA, DNAI.